Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

12
Bursa Malaysia bucks regional trend to close easier

2018-04-13 themalaymailonline
KUALA LUMPUR, April 13 — Bursa Malaysia bucked the regional trend to close easier today with the key index snapping its six-day winning streak, weighed by selling in index-linked counters led by MISC, Petronas Chemicals and Astro.
KLKBY 2445 PBLOF 1295 BSMAF 9334 7243 1818

8
KL shares down after weak opening

2018-04-13 themalaymailonline
KUALA LUMPUR, April 13 — Bursa Malaysia opened lower this morning, reversing yesterday’s gains, and dampened by profit taking ahead of the weekend.
PBLOF 1295 BSMAF 7243 1818

4
Trading ideas: Bio Osmo, Kerjaya Prospek, Dolphin International, Malakoff, MMS, Rex Industry

2018-04-13 thestar.com.my
KUALA LUMPUR: Bio Osmo Bhd , Kerjaya Prospek Group Bhd , Dolphin International Bhd , Malakoff Corp Bhd, MMS Venture Bhd and Rex Industry Bhd are among the stocks to watch, according to JF Apex Research.
0113 1589 9946 0108 BSMAF 7243 1818 5265

4
Bio Osmo buys Impiana in RTO deal

2018-04-12 thestar.com.my
PETALING JAYA: Loss-making bottled drinking water company Bio Osmo Bhd plans to buy Impiana Group’s hotel assets from its largest shareholder in a reverse takeover (RTO) deal valued at RM425.9mil.
BSMAF 7243 1818

4
Farouk sells his Impiana hotel business to Bio Osmo in RM426mil reverse takeover deal

2018-04-12 thestar.com.my
KUALA LUMPUR: Datuk Seri Farouk Abdullah, who emerged as a substantial shareholder in Bio Osmo Bhd in April last year, is injecting his Impiana hotel business in Malaysia into the loss making company in a bid to turn it around.
BSMAF 7243 1818

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...